In the course of evaluating the optimal duration of bisphosphonate treatment the FDA found little benefit of treatment beyond 5 years. [1,2] Moreover, examination of studies where bisphosphonates ...

Bisphosphonate use is associated with only a very low risk of atypical fractures to the subtrochanteric or diaphyseal femur, even in women who receive the drugs for up to 10 years, data from an ...

Examination of the patient and review of the bone specimen. Diagnosis. Giant osteoclasts after long-term bisphosphonate use, without evidence of malignancy. Management. Interpretation of the bone ...

Identical cohorts of patients are simulated by the model to compare costs and benefits for teriparatide treatment, bisphosphonate treatment, and no treatment. The simulated patients are defined by ...

Patients on dialysis were at the greatest risk. The rate of emergent hypoglycemia was significantly higher among denosumab than oral bisphosphonate users on dialysis: 3.01% vs 0%. Emergent ...

China: A recent cross-sectional study conducted in China reveals a significant prevalence of osteoporosis among patients with ...